Cherry Robinson is Global General Manager and Founder of Symphonic M.D., a new skincare brand from a collective of leading academics, doctors, researchers, inventors, and developers with the mission to unleash the potential of science to challenge skincare conventions and safely solve skincare concerns for more people. Her passion for driving brand innovation and value, coupled with her many years of experience in strategic marketing, product development, and global distribution, primed Ms. Robinson for her role to partner with Intrinsic Capital Partners, the parent company of Symphonic M.D. Working in tandem with advisory board doctors, Dr. David Leffell and Dr. David Chernoff, she was able to synthesize and apply their scientific hypothesis regarding the use of bio-functionals and cannabidiols to treat the root causes of inflammation as they relate to the most common skin concerns. The result was formulation of the proprietary bio-functional complex, BioA3 – a potent anti-inflammatory, anti-microbial, and anti-oxidant agent that ensures the stability, enhancement, and efficacy of active compounds while serving as a shield to protect against adverse reactions.
 
Prior to her current role, Ms. Robinson was Chief Executive Officer of DCL Skincare and Executive Vice President and General Manager of U.S.A. at Maison Berger Paris. She began her career in prestige fragrance marketing at Unilever, before relocating to Panama for a key management role with Chanel Beauté. Following that, Ms. Robinson was Global Director of Product Development and Innovation and then Managing Director at Schwarzkopf Limited, working across both fragrance and professional haircare. She also held the position of Global Chief Marketing Officer of Consumer Products and Pharmaceuticals at Finlayson Enterprises.